Novigenix
17.1.2024 08:02:15 CET | ACCESS Newswire | Press release
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Personalized Cancer Treatment: Breaking Barriers
Every cancer is as unique as the person it affects. Tumors are in continuous dynamic interplay with the patient's immune defenses and are adept at subverting and escaping immune control. Novigenix is on a mission to improve the cancer treatment landscape, leveraging advanced AI and RNA analysis from a routine blood draw to provide more precise insights into patient immune responses to cancer treatments, compared to conventional DNA liquid biopsies that evaluate tumor evolution through circulating tumor DNA (ctDNA). Insights into the precise dynamic of patient immune response thus pave the way for superior therapeutic discoveries in the field.
Empowering Biopharma: Unveiling LITOSeek™ at Precision Medicine World Conference
On January 24th at the Precision Medicine World Conference in Silicon Valley, Novigenix will debut LITOSeek™, a groundbreaking solution designed to expedite drug development for biopharma companies.
AI and RNA Analysis: Pioneering Healthcare Transformation
With a decade-long track record, Novigenix successfully launched Colox® blood test in Switzerland, powered by AI and RNA analysis to detect early-stage colon cancer, marking a significant departure from invasive colonoscopy procedures. By aggregating data from diverse colon cancer patients, Novigenix identified immune system biomarkers crucial for early-stage detection, enhancing treatment outcomes.
Dr. Brian Hashemi, Novigenix's CEO and Chairman, emphasized, "Our experience with Colox® underscores the potential of AI RNA analysis. Ongoing studies across various cancer types have fuelled our Knowledge Base to uncover comprehensive sets of biomarkers via liquid biopsy and AI RNA analysis. Our validated immunotherapy response biomarkers provide early prediction of patient response and we invite biopharma companies to leverage our platform for more efficient and effective drug development."
Professor Pedro Romero, M.D. Chief Medical & Scientific Officer of Novigenix, and Founding Chief Editor of the Journal of Immunotherapy of Cancer, highlights the importance of patient immune response in the development of novel therapies: "AI RNA analysis is poised to revolutionize healthcare, accelerating conventional experimental drug development with data-driven precision immune response prediction. By swiftly analyzing systemic immune responses, AI compresses analysis times, expediting traditional drug development and powering discovery of novel therapy targets."
A Team Dedicated to the Future of Cancer Care
With over 20 Ph.D.-level scientists focused on the development of the LITOSeek™ platform and advancing next-generation liquid biopsy solutions, Novigenix is pioneering precision immunology to help transform cancer treatment paradigms for better patient outcomes.
#Ends#
[1] https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/
Contact Information
Edwin Shankar
edwin.shankar@leidar.com
SOURCE: Novigenix
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Miami Fashion Week Successfully Launches Inaugural Virtual Fashion Awards Gala at Queen Miami Beach27.5.2026 18:00:00 CEST | Press release
A groundbreaking evening celebrating the future of fashion through technology, creativity, and innovation brought together global designers, AI-powered runway premieres, and industry recognition. MIAMI, FL / ACCESS Newswire / May 27, 2026 / Miami Fashion Week (MIAFW) successfully hosted its inaugural Virtual Fashion Awards on May 21, 2026, at Queen Miami Beach, hosted by Emmy Award-Winning Journalist, Lisa Petrillo. The exclusive in-person event welcomed global fashion leaders, designers, and innovators for an evening dedicated to creativity, technology, and the evolving future of fashion. Blending physical and digital experiences, the gala featured both produced and in-development collections, highlighting the fusion of emerging technologies with traditional craftsmanship. A live model showcase complemented the AI-powered virtual runway presentations, creating a fully immersive experience for attendees. Images (Courtesy of Miami Fashion Week): here Official Gala Recap and Virtual Pres
OMP Launches Unison Express to Fast-Track Supply Chain Planning from Ambition to Early Value27.5.2026 15:00:00 CEST | Press release
Ready-to-deploy solution delivers value quickly through proven industry best practices ANTWERPEN, BE / ACCESS Newswire / May 27, 2026 / OMP, a leading provider of AI-powered supply chain planning solutions, today announced the launch of Unison Express - an industry-specific, ready-to-deploy planning offering for mid-market companies looking to move beyond the tools and processes they have outgrown. Unison Express enables teams to realize value quickly while establishing a strong planning foundation that scales with their business over time. From spreadsheets to structured planning Organizations across industries face mounting pressure to modernize supply chain planning. Yet implementation projects can feel long, costly, and difficult to justify, especially when teams still rely on tools and processes they have outgrown, such as spreadsheets, legacy systems, and manual coordination. The result is higher operational risk and slower, less coordinated decision-making. Unison Express bridge
SINTEF Selects Power to Hydrogen to Produce Green Hydrogen for the PYROCO2 EU Green Deal Project in Norway27.5.2026 10:35:00 CEST | Press release
Power to Hydrogen's Second Commercial Project Extends Industrial-Scale AEM Electrolysis Into Chemicals Manufacturing COLUMBUS, OH / ACCESS Newswire / May 27, 2026 / Power to Hydrogen (P2H2), a developer of anion exchange membrane (AEM) electrolyzer systems, today announced a binding commercial order from SINTEF, one of Europe's largest research institutes, for a half-megawatt AEM electrolyzer system scheduled to be delivered in Q4 2026. The system will be deployed at SINTEF's facility in Tiller, Norway, where it will produce green hydrogen for a novel gas fermentation process that combines green hydrogen and captured carbon dioxide to produce zero-emission acetone, a platform chemical used across solvents, plastics, and industrial value chains. The order is Power to Hydrogen's second commercial project, following the company's landmark project at the Port of Antwerp-Bruges - set to be commissioned this summer - and marks an important expansion of AEM electrolysis into green chemicals a
Caldwell Strengthens Consumer and Private Equity Capabilities with Addition of Gabino Stuyck in Madrid27.5.2026 09:30:00 CEST | Press release
TORONTO, ON AND MADRID, ES / ACCESS Newswire / May 27, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Gabino Stuyck as a Partner in the firm's Consumer Practice. Based in Madrid, Stuyck's appointment expands Caldwell's presence in Europe and strengthens the firm's capabilities across consumer, private equity, technology, sports, and digital transformation leadership assignments globally. Caldwell welcomes Gabino Stuyck as a partner in the firm's Consumer Practice, strengthening the firm's global consumer and private equity capabilities. Based in Madrid, Stuyck advises private equity firms, portfolio companies, and global organizations on senior executive and board appointments across Europe, the Middle East, Latin America, and North America. With more than 17 years of executive search experience and more than 200 completed mandates worldwide, he is recognized for building high-impact leadership teams in investor-backed, high-growth
LinkShadow is Positioned in the Visionaries Quadrant in the 2026 Gartner(R) Magic Quadrant(TM) for Network Detection and Response (NDR)23.5.2026 17:00:00 CEST | Press release
Recognized for Vision. Driven by Innovation. Advancing AI-powered network detection and response through connected intelligence, contextual visibility, and modern cyber defense. ATHENS, GA / ACCESS Newswire / May 23, 2026 / LinkShadow has been positioned in the Visionaries Quadrant of the 2026 Gartner® Magic Quadrant™ for Network Detection and Response. We are recognized for our completeness of vision and ability to execute. We believe this recognition highlights a differentiated approach to NDR that is redefining how organizations detect and respond to modern network threats. As cyber threats grow more sophisticated and fast moving, security teams are challenged by fragmented visibility, overwhelming alert volumes, and limited context. LinkShadow addresses these challenges through a distinct strategy that combines AI driven analytics with deep contextual awareness and real time correlation across network activity. This enables organizations to move beyond isolated alerts and toward a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom